ADAR1 Capital Management LLC Sells 118,321 Shares of Chimerix, Inc. (NASDAQ:CMRX)

ADAR1 Capital Management LLC lessened its stake in Chimerix, Inc. (NASDAQ:CMRX - Free Report) by 49.2% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 122,236 shares of the biopharmaceutical company's stock after selling 118,321 shares during the period. ADAR1 Capital Management LLC owned 0.14% of Chimerix worth $425,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of CMRX. Rosalind Advisors Inc. bought a new stake in shares of Chimerix during the fourth quarter worth $10,614,000. Connor Clark & Lunn Investment Management Ltd. raised its holdings in Chimerix by 24.6% during the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 429,513 shares of the biopharmaceutical company's stock worth $1,495,000 after purchasing an additional 84,801 shares during the last quarter. Bender Robert & Associates bought a new stake in Chimerix during the 4th quarter worth about $37,000. Charles Schwab Investment Management Inc. acquired a new position in Chimerix during the 4th quarter valued at about $183,000. Finally, Palumbo Wealth Management LLC acquired a new stake in shares of Chimerix during the 4th quarter worth approximately $221,000. Institutional investors and hedge funds own 45.42% of the company's stock.

Wall Street Analyst Weigh In

CMRX has been the topic of several analyst reports. StockNews.com assumed coverage on shares of Chimerix in a report on Tuesday. They issued a "hold" rating on the stock. Jefferies Financial Group reissued a "hold" rating and issued a $8.50 price target (down previously from $10.00) on shares of Chimerix in a research note on Wednesday, March 5th. Wedbush reaffirmed a "neutral" rating and set a $8.55 price objective (up from $7.00) on shares of Chimerix in a research note on Wednesday, March 5th. Finally, HC Wainwright reissued a "neutral" rating and issued a $8.55 target price (down previously from $11.00) on shares of Chimerix in a research note on Wednesday, March 5th.

Chimerix Stock Performance

NASDAQ:CMRX traded down $0.01 during trading hours on Friday, hitting $8.52. The stock had a trading volume of 1,537,676 shares, compared to its average volume of 2,210,031. The business's 50 day moving average is $6.95 and its 200-day moving average is $3.73. The company has a market cap of $799.21 million, a price-to-earnings ratio of -9.06 and a beta of -0.17. Chimerix, Inc. has a one year low of $0.75 and a one year high of $8.55.

Chimerix (NASDAQ:CMRX - Get Free Report) last issued its quarterly earnings data on Friday, March 21st. The biopharmaceutical company reported ($0.25) EPS for the quarter, topping the consensus estimate of ($0.26) by $0.01. The business had revenue of $0.06 million for the quarter, compared to analyst estimates of $0.31 million. On average, sell-side analysts anticipate that Chimerix, Inc. will post -0.99 EPS for the current fiscal year.

Insider Transactions at Chimerix

In other news, CEO Michael T. Andriole sold 7,370 shares of the stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $4.52, for a total transaction of $33,312.40. Following the completion of the sale, the chief executive officer now owns 609,603 shares of the company's stock, valued at $2,755,405.56. This represents a 1.19 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders have sold a total of 20,760 shares of company stock valued at $91,175 over the last 90 days. 13.10% of the stock is owned by company insiders.

Chimerix Profile

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.